Bilieye

Company Overview

Snapshot

Founded in May 2024 by Chen Binyamin, Bilieye operates with 1-10 employees. The company has secured $700,000 in total capital across one funding round. In March 2025, Bilieye completed a Pre-Seed funding round.

Business overview

Bilieye is innovating neonatal care through a non-invasive app that enables remote monitoring of bilirubin levels in newborns. This technology allows parents and healthcare providers to assess a baby's jaundice risk using a smartphone photo of the baby's eyes, eliminating the need for traditional invasive blood tests. The software is designed to be effective across all skin tones, enhancing accessibility and reducing stress for families. Bilieye operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Digital Medical Diagnostics, serving both consumers (parents) and healthcare providers.

Company Intelligence Q&A

What is Bilieye's core technology?

Bilieye's core technology is a non-invasive app that utilizes smartphone photography to remotely monitor bilirubin levels in newborns, providing an alternative to traditional blood tests for jaundice detection.

When was Bilieye founded and by whom?

Bilieye was founded in May 2024 by Chen Binyamin.

What is Bilieye's mission?

Bilieye's mission is to enhance the healthcare experience for families by offering a safe, effective, and accessible alternative to traditional bilirubin monitoring methods for newborns.

What markets does Bilieye target?

Bilieye targets geomarkets including the Americas, India, and Israel, aiming to provide its digital healthcare solution to a global audience.

What is the current product stage of Bilieye's solution?

Bilieye's product, the Bilieye app, is currently in the Clinical Trial stage. The company is actively conducting trials to validate its efficacy and safety, moving towards regulatory approval and market readiness.